Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00017147 · ClinicalTrials.gov registry record · Phase 3
S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or Gliosarcoma
A Phase 3 study, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 3
- Development phase
- 183
- Enrollment target
NCT00017147 is a Phase 3 study that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 183 participants.
The verdict
NCT00017147, a Phase 3 study, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 183 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. O6-benzylguanine may help carmustine kill more tumor cells by making tumor cells more sensitive to the drug. It is not yet known whether radiation therapy and carmustine are more effective with or without O6-benzylguanine. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy plus carmustine with or without O6-benzylguanine in treating patients who have newly diagnosed glioblastoma multiforme or gliosarcoma.
Interventions
- RADIATION radiation therapy
- DRUG carmustine
- DRUG O6-Benzylguanine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 183 participants |
| Start Date | 2001-09 |
| Est. Completion | 2012-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00017147
The ClinicalTrials.gov registry entry for NCT00017147 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 183 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which radiation therapy is the first listed.
NCT00017147 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00017147 about?
NCT00017147 is a clinical study titled "S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or Gliosarcoma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. O6-benzylguanine may help carmustine kill more tumor cells by making tumor cells more sensitive to the drug. It is ...
What is the current status of trial NCT00017147?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 183 participants. The study started on 2001-09. Estimated completion is 2012-11.
What interventions are being tested in trial NCT00017147?
The interventions under investigation include: radiation therapy (RADIATION), carmustine (DRUG), O6-Benzylguanine (DRUG).
Who is sponsoring clinical trial NCT00017147?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.